4家A股上市公司同日公告，将于下周一复牌。 值得注意的是，威高股份同时是威高血净的第二大股东，三者同属威高集团体系，实际控制人均为陈学利，因 此本次交易本质是"威高系"内部的资产优化整合，不会导致公司实际控制人变更，亦不构成重组上市。 威高血净表示，本次交易完成后，公司可以通过整合标的公司技术积累和产品布局，将产品线扩展到医药包材 领域。同时，本次交易完成后，通过充分协同上市公司自身中空纤维过滤技术优势与威高普瑞在生物制药领域 的丰富客户资源，可以实现双方在生物制药滤器业务上产品技术储备与销售渠道的双向赋能，共同开拓以生物 制药滤器为重点的生物制药上游业务市场。 中元股份（300018）10月31日公告，10月30日，公司原实控人尹健等8人与朱双全、朱顺全签订《表决权委托 协议》，尹健等8人将合计持有中元股份1.01亿股股份的表决权委托给朱双全、朱顺全行使。同日，朱双全、 朱顺全、朱梦茜与尹健等8人签署一致行动协议，约定表决权委托期间，尹健等8人成为朱双全、朱顺全、朱梦 茜的一致行动人。《表决权委托协议》生效后，朱双全、朱顺全持有上市公司的表决权比例为20.71%。截至 10月30日，朱梦茜直接持有上市公司的 ...

智通财经APP讯，威高血净(603014.SH)发布公告，公司拟发行股份购买威高股份、威海盛熙和威海瑞 明持有的山东威高普瑞医药包装有限公司(简称"威高普瑞")100%股权。公司股票将于2025年11月3日(星 期一)开市起复牌。 本次交易完成后，公司可以通过整合标的公司技术积累和产品布局，将产品线扩展到医药包材领域。同 时，本次交易完成后，通过充分协同上市公司自身中空纤维过滤技术优势与标的公司在生物制药领域的 丰富客户资源，可以实现双方在生物制药滤器业务上产品技术储备与销售渠道的双向赋能，共同开拓以 生物制药滤器为重点的生物制药上游业务市场。 ...

Core Viewpoint - Huaren Pharmaceutical Co., Ltd. is facing significant financial challenges, including a major loss attributed to credit impairment losses related to receivables from Guoyao Medicinal Materials Co., Ltd. [1][4] Group 1: Shareholder Actions - Huaren Century Group, a major shareholder, plans to reduce its stake in Huaren Pharmaceutical by up to 1% between June 24, 2025, and September 23, 2025, amounting to no more than 11,822,100 shares [1][2] - Huaren Century Group's shareholding has decreased from 53% in 2014 to 7.9% currently, following multiple rounds of share reductions [2][3] - Red Tower Innovation Investment Co., Ltd., the third-largest shareholder, has also been reducing its holdings, having sold 23,619,960 shares for a total of 74.16 million yuan from August 22, 2024, to April 29, 2025 [2] Group 2: Financial Performance - Huaren Pharmaceutical reported a net loss of 1.368 billion yuan for 2024, marking the worst performance since its listing in 2010, effectively erasing all profits accumulated over 13 years [3][4] - The company has cumulatively achieved a net profit of 1.197 billion yuan from 2010 to 2023, indicating that the loss in 2024 surpassed all previous profits [3] Group 3: Credit Impairment and Debt Recovery - The significant loss is primarily due to the full credit impairment of receivables amounting to 1.3478 billion yuan owed by Guoyao Medicinal Materials [4][6] - Huaren Pharmaceutical's subsidiary, Qingdao Huaren Pharmaceutical Co., Ltd., had established a business relationship with Guoyao Medicinal Materials, resulting in 1.41 billion yuan in receivables [4][5] - A repayment agreement was signed in January 2024, allowing Guoyao Medicinal Materials three years to settle the debt, but the execution of this agreement remains uncertain [6] Group 4: Guoyao Medicinal Materials' Issues - Guoyao Medicinal Materials is not controlled by the state-owned China National Pharmaceutical Group, despite its name, and has faced various operational issues [5][6] - The company has multiple enforcement actions against it, totaling 106 million yuan, and has been subject to numerous restrictions and judgments [6]